Options on this firm's blockbuster cost a little but pay off big.
Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.
We see opportunity as fleeing investors trigger an irrational sell-off.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...